Loading...
•
Jun 30, 2022
Iovance Q2 2022 Earnings Report
Reported second quarter and first half 2022 financial results and corporate updates.
Key Takeaways
Iovance reported a net loss of $99.3 million, or $0.63 per share, for the second quarter ended June 30, 2022. The company had $430.9 million in cash, cash equivalents, investments and restricted cash at June 30, 2022, which is expected to fund operations into 2024. The BLA submission for lifileucel in metastatic melanoma is on track for August 2022.
Submitted the BLA for lifileucel in metastatic melanoma.
Preparing for commercialization.
Advancing our robust immuno-oncology pipeline.
Finalizing BLA to begin submission this month following pre-BLA meeting in late July.
Forward Guidance
The cash position is expected to be sufficient to fund current and planned operations into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...